UroGen Pharma Ltd (URGN)
13.22
+0.01
(+0.08%)
USD |
NASDAQ |
May 17, 16:00
13.22
0.00 (0.00%)
After-Hours: 20:00
UroGen Pharma Net Income (Quarterly): -32.29M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -32.29M |
| December 31, 2023 | -26.02M |
| September 30, 2023 | -21.88M |
| June 30, 2023 | -24.14M |
| March 31, 2023 | -30.21M |
| December 31, 2022 | -28.87M |
| September 30, 2022 | -25.83M |
| June 30, 2022 | -26.69M |
| March 31, 2022 | -28.39M |
| December 31, 2021 | -28.45M |
| September 30, 2021 | -30.21M |
| June 30, 2021 | -26.22M |
| March 31, 2021 | -25.94M |
| December 31, 2020 | -30.53M |
| September 30, 2020 | -28.82M |
| June 30, 2020 | -31.35M |
| Date | Value |
|---|---|
| March 31, 2020 | -37.79M |
| December 31, 2019 | -38.97M |
| September 30, 2019 | -22.25M |
| June 30, 2019 | -22.48M |
| March 31, 2019 | -21.44M |
| December 31, 2018 | -23.72M |
| September 30, 2018 | -20.53M |
| June 30, 2018 | -18.03M |
| March 31, 2018 | -13.38M |
| December 31, 2017 | -10.09M |
| September 30, 2017 | -0.298M |
| June 30, 2017 | -6.199M |
| March 31, 2017 | -3.417M |
| December 31, 2016 | 12.92M |
| September 30, 2016 | -7.987M |
| June 30, 2016 | -3.317M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-38.97M
Minimum
Dec 2019
-21.88M
Maximum
Sep 2023
-28.37M
Average
-28.42M
Median
Net Income (Quarterly) Benchmarks
| Agenus Inc | -61.89M |
| Exelixis Inc | 37.32M |
| Geron Corp | -55.39M |
| Protalix BioTherapeutics Inc | -4.595M |
| InfuSystems Holdings Inc | -1.112M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 18.78M |
| Total Expenses (Quarterly) | 44.52M |
| EPS Diluted (Quarterly) | -0.97 |
| Enterprise Value | 411.18M |
| Gross Profit Margin (Quarterly) | 90.80% |
| Profit Margin (Quarterly) | -171.9% |
| Earnings Yield | -25.26% |
| Normalized Earnings Yield | -20.94 |